Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Diabetes is a major risk factor for cardiovascular disease, and recent advances in research indicate that a detailed understanding of the pathophysiology of its effects is mandatory to reduce diabetes-related mortality and morbidity. Advanced Glycation End Products (AGEs) play a central role in the genesis and progression of complications of both type 1 and type 2 diabetes mellitus, and have been found to be important even in non-diabetic patients as a marker of cardiovascular disease. AGEs have a profound impact on patient's prognosis regardless of the glycemic control, and therefore pharmacologic approaches against AGEs accumulation have been proposed over the years to treat cardiovascular diseases, parallel to a more detailed understanding of AGEs pathophysiology. Compounds with anti-AGEs effects are currently under investigation in both pre-clinical and clinical scenarios, and many of the drugs previously used to treat specific diseases have been found to have AGE-inhibitory effects. Some products are still in "bench evaluation", whereas others have been already investigated in clinical trials with conflicting evidences. This review aims at summarizing the mechanisms of AGEs formation and accumulation, and the most relevant issues in pre-clinical and clinical experiences in anti-AGEs treatment in cardiovascular research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261
Understanding RAGE, the receptor for advanced glycation end products
Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., & Nawroth, P. P. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0688-7 · Cited by 1,297
Role of advanced glycation end products in cellular signaling
Ott, C., Jacobs, K., Haucke, E., Navarrete Santos, A., Grune, T., & Simm, A. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.016 · Cited by 1,150
Schmidt, A. M., Hori, O., Chen, J. X., Li, J. F., Crandall, J., Zhang, J., Cao, R., Yan, S. D., Brett, J., & Stern, D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118175 · Cited by 896
Hammes, H.-P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D., et al. (2003) · Nature Medicine · doi:10.1038/nm834 · Cited by 785
YONEKURA, H., YAMAMOTO, Y., SAKURAI, S., PETROVA, R. G., ABEDIN, M. J., LI, H., YASUI, K., TAKEUCHI, M., MAKITA, Z., TAKASAWA, S., et al. (2003) · Biochemical Journal · doi:10.1042/bj20021371 · Cited by 716
Reaction of Monosaccharides with Proteins: Possible Evolutionary Significance
Bunn, H. F., & Higgins, P. J. (1981) · Science · doi:10.1126/science.12192669 · Cited by 598
Thornalley, P. J. (1996) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(95)02054-3 · Cited by 591
Li, J., & Schmidt, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.26.16498 · Cited by 525
Cited by
Lampi, M. C., & Reinhart-King, C. A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0475 · Cited by 551
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective
Bongarzone, S., Savickas, V., Luzi, F., & Gee, A. D. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00058 · Cited by 313
Cellular mechanisms underlying obesity-induced arterial stiffness
Aroor, A. R., Jia, G., & Sowers, J. R. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00235.2016 · Cited by 181
Lyu, C., Kong, W., Liu, Z., Wang, S., Zhao, P., Liang, K., Niu, Y., Yang, W., Xiang, C., Hu, X., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01019-z · Cited by 67
“Currently, there are no AGE-targeted therapeutics approved for the market 8 , and some candidates, such as aminoguanidine and alagebrium, have shown inconsistent results in animal studies and clinical trials 44 .”
Singh, H., & Agrawal, D. K. (2022) · Drug Development Research · doi:10.1002/ddr.21971 · Cited by 57
Metadata
- Authors
- Nenna, A., Spadaccio, C., Lusini, M., Ulianich, L., Chello, M., & Nappi, F.
- Venue
- Recent Advances in Cardiovascular Drug Discovery (Formerly Recent Patents on Cardiovascular Drug Discovery)
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2016-01-11
- Volume
- 10
- Issue
- 1
- Pages
- 10-33
- ISSN
- 1574-8901 (ISSN-L)
- OpenAlex
- W1942113823
- Cited by
- 43
- References
- 22
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications. https://app.cochat.ai/papers/10.2174/1574890110666151104120039
- The paper
- Nenna, A., Spadaccio, C., Lusini, M., Ulianich, L., Chello, M., & Nappi, F. (2016). Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications. Recent Advances in Cardiovascular Drug Discovery (Formerly Recent Patents on Cardiovascular Drug Discovery). https://doi.org/10.2174/1574890110666151104120039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.